Over 300 patients now enrolled worldwide in clinical trials for a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s

Professor Claude Wischik, Executive Chairman of TauRx Therapeutics and Dr. Sharon Cohen, Medical Director of the Toronto Memory Program Announce the Canadian Launch of Pivotal Alzheimer’s Research

Clinical trials get under way in the UK with a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s

Demographic and societal impact of Alzheimer’s in China will grow exponentially if its current course is not averted, according to pioneer in tau pathology, a hallmark of Alzheimer’s Disease A new treatment targeting tau pathology is tomorrow’s hope for a brighter future, and Phase 3 clinical studies are bringing us closer to that goal.

Dundee Corporation maintains 5% stake in company developing a revolutionary treatment for Alzheimer’s Disease.